サンプル依頼リスト カート
  • English
  • Korean
表紙：消化不良治療薬の世界市場 - 2023年～2030年
市場調査レポート
商品コード
1374808

消化不良治療薬の世界市場 - 2023年～2030年

Global Dyspepsia Drugs Market -2023-2030

出版日
ページ情報
英文 186 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
消化不良治療薬の世界市場 - 2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

消化不良とも呼ばれ、飲食後に上腹部に不快感や痛みを感じる疾患。これは病気ではなく、胃食道逆流症（GERD）やその他の疾患の症状です。

胃酸過多、胃炎、消化性潰瘍、胃食道逆流症（GERD）、食生活やストレスなどの生活習慣など、さまざまな原因が複合的に絡み合って起こる症状です。

世界の人口の高齢化、食やライフスタイルの動向の変化はすべて消化不良症状の増加に寄与しており、市場の成長を促進しています。特にプロトンポンプ阻害薬（PPI）のカテゴリーにおける薬剤研究の技術的進歩は、新規かつ非常に効果的な消化不良治療薬を生み出しています。さらに、一般用医薬品（OTC）へのシフトは、消費者に手軽で容易に入手可能な解決策を提供しています。

市場促進要因：市場抑制要因

消化不良治療におけるOTC薬への嗜好の高まり

一般用医薬品（OTC）消化不良治療薬は、薬局などの小売店で容易に入手できる非処方薬であり、腹部不快感や腹部膨満感などの消化不良の症状を緩和するように設計されています。市販の消化不良治療薬の人気の高まりは、製薬会社を後押ししています。

プロトンポンプ阻害薬は、消化不良を治療するために主に使用される薬です。例えば、Drug Watch 2023の記事によると、プロトンポンプ阻害薬（PPI）は世界で最もよく使用されている薬の一つです。米国では毎年1,500万人近くがPPIを使用しています。

さらに、多くの製薬会社が消化不良の一般用医薬品を発売しています。例えば、2022年1月、グレンマークUSA社は、ウォックハルト社からファモチジン、セチリジン塩酸塩、ランソプラゾールといった4つのOTC薬のANDASを買収しました。これらのOTC医薬品は、特に消化不良、胸やけ、抗アレルギー、酸逆流の治療に使用されます。

さらに、消化不良の有病率の増加、人口の高齢化、胃腸の健康に対する意識の高まり、ライフスタイルや食習慣の変化は、予測期間中に世界の消化不良薬市場を牽引すると予想されるその他の主な要因の一部です。

市場力学：市場抑制要因

消化不良薬に関連する副作用は、市場を抑制する主要な要因の一つです。特に胃酸の分泌を減少させる薬剤は、頭痛や下痢、吐き気を引き起こす可能性があります。

さらに、代替治療の選択肢があることも市場の成長に影響を与える可能性があります。消化不良を抱える人々は、医薬品による治療よりも、漢方薬、食生活の改善、ライフスタイルの変更などの代替治療を好むかもしれないです。これらの代替的アプローチは、標準的な薬理学的治療から患者を引き離す可能性があり、それによって予測期間中の市場成長の可能性に影響を与えます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 消化不良治療におけるOTC医薬品への嗜好の高まり
    • 抑制要因
      • 消化不良治療薬に伴う副作用
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMI意見

第6章 COVID-19分析

第7章 疾患タイプ別

  • 機能性消化不良
  • 器質性消化不良

第8章 薬剤タイプ別

  • プロトンポンプ阻害薬
    • ランソプラゾール
    • オメプラゾール
    • エソメプラゾール
  • H-2受容体拮抗薬
    • シメチジン
    • ファモチジン
    • ニザチジン
  • 制酸剤
      • 炭酸カルシウム
      • ロペラミド
      • シメチコン
      • 炭酸水素ナトリウム
  • 抗生物質
      • アモキシシリン
      • クラリスロマイシン
      • メトロニダゾール
      • テトラサイクリン
  • プロキネティクス
      • ベタネコール
      • メトクロプラミド
  • 抗うつ薬

第9章 投与経路別

  • 経口
  • 非経口

第10章 モード別

  • 市販薬
  • 処方箋

第11章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第12章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他のアジア太平洋
  • 中東・アフリカ

第13章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第14章 企業プロファイル

  • Takeda Pharmaceutical Company Limited.
    • 会社概要
    • 製品タイプのポートフォリオと説明
    • 財務概要
    • 主な発展
  • Sanofi
  • Haleon plc.
  • Procter & Gamble
  • Abbott
  • Pfizer Inc.
  • Woodward Pharma Services LLC
  • Lannett Company, Inc.
  • ANI Pharmaceuticals, Inc.
  • Salix Pharmaceuticals, Inc

第15章 付録

目次
Product Code: PH4396

Overview

Dyspepsia also referred as indigestion that casues discomfort or pain in the upper abdomen, often after eating or drinking. It is not a disease but symptom of gastroesophageal reflux disease (GERD) and other conditions.

Dyspepsia is a combination of symptoms caused by a variety of underlying reasons such as excessive stomach acid production, gastritis, peptic ulcers, gastroesophageal reflux disease (GERD), and lifestyle factors such as dietary intake and stress.

The aging global population, as well as changing food and lifestyle trends, all contribute to an increase in dyspeptic symptoms, propelling market growth. Technological advances in drug research, particularly in the Proton Pump Inhibitor (PPI) category, have resulted in novel and very effective dyspepsia treatments. Furthermore, the shift toward over-the-counter (OTC) dyspepsia medications provides consumers with easy and readily available solutions.

Market Dynamics: Drivers and Restraints

The increasing preference for OTC drugs for dyspepsia treatment

Over-the-counter (OTC) dyspepsia drugs are non-prescription medications that are readily available in retail outlets such as pharmacies and are designed to alleviate symptoms of dyspepsia such as abdominal discomfort and bloating. The growing popularity of over-the-counter dyspepsia medications has pushed pharmaceutical companies.

Proton pump inhibitors are the mostly used drugs to treat dyspepsia. For instance, according to the Drug Watch 2023 article, proton pump inhibitors (PPIs) are among the most commonly used drugs in the world. Almost 15 million people in the U.S. use PPIs every year.

Furthermore, many pharmaceutical companies are launching the OTC drugs for dyspepsia. For instance, in January 2022, Glenmark USA acquired ANDAS for four OTC drugs such as famotidine, cetirizine, hydrochloride, lansoprazole from Wockhardt. These OTC drugs are specifically used to treat indigestion, heartburn, anti-allergy, and acid reflux.

Furthermore, the increasing prevalence of dyspepsia, aging population, growing awareness of gastrointestinal health and changing lifestyles and dietary habits are some of the other major factors that are expected to drive the global dyspepsia drugs market over the forecast period.

Market Dynamics: Restraint

The side effects associated with dyspepsia drugs is one major factor to restrain the market. Some of the dyspepsia drugs, especially those that reduce stomach acid production, may cause headaches, diarrhea and nausea.

Furthermore, the availability of alternative treatment options can affect the market growth. Those individuals with dyspepsia may prefer alternative treatment such as herbal medicines, dietary modifications, or lifestyle changes over pharmaceutical treatments. These alternative approaches have the potential to draw patients away from standard pharmacological treatments, thereby affecting the market's growth potential over the forecast period.

Segment Analysis

The global dyspepsia drugs is segmented based on disease type, drug type, route of administration, mode, distribution channel and region.

The proton pump inhibitor segment accounted for approximately 38.2 % of the market share

The proton pump inhibitors (PPIs) from the product type segment accounted for 38.2% and it is expected to be dominated during the forecast period. The proton pump inhibitors (PPIs) are considered as first line treatment for for functional dyspepsia. PPIs are among the strongest drugs available for gastric suppression that improves functional dyspepsia.

Furthermore, according to NHS Greater Glasgow and Clyde 2022 article, PPIs stands second in most commonly prescribed drug class with almost 1.5 million prescriptions issued yearly by primary care alone. Among these drug class, omeprazole and lansoprazole are higly preferred choice for adults. Also, its availability at OTC makes this drug class a preferred choice for individuals suffering from dyspepsia.

The cost-effectiveness and broad availability of medications like omeprazole, a typical proton pump inhibitor (PPI), increase their popularity among both patients and healthcare practitioners. Omeprazole's modest cost, around $100.37 for 100 capsules, enables accessibility for a wide range of people, particularly those without complete health insurance coverage. Thus, owing to the above factors the segment is expected to dominate over the forecast period.

Geographical Analysis

North America accounted for approximately 37.4% of the market share in 2022

North America is estimated to hold about 37.4% of the total market share throughout the forecast period, owing to the increasing product approvals, rising geriatric population, collaboration with the key players, and others that will drive this region further during the forecast period.

For instance, in March 2023, Marksans Pharma Ltd obtained final approval from the U.S. Food and Drug Administration for its generic version of Famotidine tablets, which are used to treat acid indigestion and heartburn. The US Food and Drug Administration (USFDA) has approved an abbreviated new drug application (ANDA) for Famotidine tablets in strengths of 10 mg and 20 mg for over-the-counter (OTC) usage.

Furthermore, the increasing geriatric population in U.S. is major factor in driving the market forwards. Dyspepsia is more common in elderly people, as it decreases in the production of digestive juices (such as bile, saliva, gastric juice, and enzymes). For instance, according to United States Census Bureau 2023 report, in U.S. older population aging 65 and above has reached about 55.8 million or 16.8%, as it has grown nearly five times faster than the total population over 100 years. Thus, as the age increases the probability of having dyspepsia grows, thereby driving the region market forward over the forecast period.

COVID-19 Impact Analysis

COVID-19 had a substantial impact on the global dyspepsia drugs market, as it is a stress-sensitive gut-brain condition, and the COVID-19 epidemic has caused significant anxiety and stress. A population-based survey was conducted to assess the influence of the COVID-19 pandemic on the gastrointestinal and psychological symptoms of FD. According to the survey, the COVID-19 pandemic had a negative impact on FD/IBS individuals, with respondents indicating FD-IBS overlap syndrome as the most important independent factor linked with worsening gastrointestinal symptoms.

Moreover, a clinical trial is ongoing to look into the effect of COVID-19 infection on the symptoms of functional dyspepsia (FD). The study's goal is to see if COVID-19 infection causes FD or worsens the symptoms of pre-existing FD. The trial is prospective observational research in which patients with FD and COVID-19 infection will be included. The researchers will evaluate the severity of FD symptoms before and after COVID-19 infection in a control group of FD patients who did not develop COVID-19.

Competitive Landscape

The major global players in the dyspepsia drugs market include: Takeda Pharmaceutical Company Limited, Sanofi, Haleon plc., Procter & Gamble, Abbott, Pfizer Inc., Woodward Pharma Services LLC, Lannett Company, Inc., ANI Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc and among others.

Key Developments

  • In January 2023, metaMe Health, Inc., a prescription digital therapeutics (PDT) company, agreed to licensed gut-directed hypnotherapy protocol for functional dyspepsia, a chronic disorder of the upper gastrointestinal tract that currently lacks substantially effective therapy options.
  • In July 2022, Meiji Seika Pharma and Zeria Pharmaceutical granted regulatory approval in Thailand for Acofide (acotiamide) to treat functional dyspepsia.

Why Purchase the Report?

  • To visualize the global dyspepsia drugs market segmentation-based on disease type, drug type, route of administration, mode, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of dyspepsia drugs market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global dyspepsia drugs market report would provide approximately 77 tables, 77 figures, and 185 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Disease Type
  • 3.2. Snippet by Drug Type
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Mode
  • 3.5. Snippet by Distribution Channel
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Driver
      • 4.1.1.1. The increasing preference for OTC drugs for dyspepsia treatment
    • 4.1.2. Restraints
      • 4.1.2.1. Side effects associated with the dyspepsia drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 7.1.2. Market Attractiveness Index, By Disease Type
  • 7.2. Functional Dyspepsia*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Organic Dyspepsia

8. By Drug Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 8.1.2. Market Attractiveness Index, By Drug Type
  • 8.2. Proton Pump Inhibitors*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
      • 8.2.2.1. Lansoprazole
      • 8.2.2.2. Omeprazole
      • 8.2.2.3. Esomeprazole
  • 8.3. H-2-receptor Antagonists
      • 8.3.1.1. Cimetidine
      • 8.3.1.2. Famotidine
      • 8.3.1.3. Nizatidine
  • 8.4. Antacids
      • 8.4.1.1. Calcium Carbonate
      • 8.4.1.2. Loperamide
      • 8.4.1.3. Simethicone
      • 8.4.1.4. Sodium Bicarbonate
  • 8.5. Antibiotics
      • 8.5.1.1. Amoxicillin
      • 8.5.1.2. Clarithromycin
      • 8.5.1.3. Metronidazole
      • 8.5.1.4. Tetracycline
  • 8.6. Prokinetics
      • 8.6.1.1. Bethanechol
      • 8.6.1.2. Metoclopramide
  • 8.7. Antidepressants

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Oral*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Parenteral

10. By Mode

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode
    • 10.1.2. Market Attractiveness Index, By Mode
  • 10.2. Over the Counter*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Prescription

11. By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.1.2. Market Attractiveness Index, By Distribution Channel
  • 11.2. Hospital Pharmacies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Retail Pharmacies
  • 11.4. Online Pharmacies

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode
    • 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode
    • 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. UK
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode
    • 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia-Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode
    • 12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia-Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode
    • 12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Market Positioning/Share Analysis
  • 13.3. Mergers and Acquisitions Analysis

14. Company Profiles

  • 14.1. Takeda Pharmaceutical Company Limited.
    • 14.1.1. Company Overview
    • 14.1.2. Product Type Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. Sanofi
  • 14.3. Haleon plc.
  • 14.4. Procter & Gamble
  • 14.5. Abbott
  • 14.6. Pfizer Inc.
  • 14.7. Woodward Pharma Services LLC
  • 14.8. Lannett Company, Inc.
  • 14.9. ANI Pharmaceuticals, Inc.
  • 14.10. Salix Pharmaceuticals, Inc

LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us